Please login to the form below

Not currently logged in
Email:
Password:

Dr Stephen Mascioli and Dana Alexander join Anika Therapeutics

They become chief medical officer and chief operations officer respectively

Anika Therapeutics Dr Stephen MascioliAnika Therapeutics has appointed Dr Stephen Mascioli as its new chief medical officer and Dana Alexander as its chief operations officer.

In their new roles, both will report to the orthopedics medicines firm's president and chief executive officer, Dr Charles Sherwood.

Sherwood said: “We're pleased to add Dr Mascioli and Mr Alexander to our executive leadership team as we enter a pivotal phase in Anika's growth, which is driven by pipeline advancement and global commercial expansion.

“With Dr Mascioli spearheading the preclinical and clinical development of our robust pipeline and Mr. Alexander overseeing and building our manufacturing and operations capabilities, we anticipate tremendous progress in executing our long-term growth strategy.”

Dr Mascioli (pictured above) brings 25 years of medical leadership experience to Anika, having recently held the then newly-created chief medical officer role at Terumo Americas Holdings.

Prior to joining Terumo, Dr Mascioli served as chief medical officer of the vascular therapies division of Covidien, a medical devices company, and has held leadership positions at Boston Scientific and American Medical Systems.

Dr Mascioli said: “I'm excited to drive the clinical development strategy, rally the support of key physician thought leaders, and work with our regulatory team to bring Anika's important therapeutic advances to patients.”

Anika Therapeutics Dana AlexanderMeanwhile, Alexander (pictured left) brings nearly two decades of operational expertise to his role, having spent the last 14 years in increasingly senior manufacturing and supply chain management positions at Genzyme Corporation.

Most recently, Alexander held the role of senior director of biologics manufacturing operations in which he was responsible for overseeing the operations of Genzyme's flagship biologics plant.

Alexander said: “I look forward to building upon Anika's strong operational framework and processes to establish a manufacturing and production powerhouse that will function as the cornerstone of Anika's global commercial expansion effort.”

12th April 2016

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics